✦ LIBER ✦

145: ID/KLH active immunotherapy (FAVID®) following high dose therapy (HDT) and autologous stem cell transplantation (ASCT) for non-hodgkin’s lymphoma (NHL)

✍ Scribed by P.P. Holman; M. deMagalhaes-Silverman; S. Corringham; J.E. Castro; E. Carrier; T. Lane; D. Gold; E. Ball

Book ID: 116279326
Publisher: Elsevier Science
Year: 2007
Tongue: English
Weight: 55 KB
Volume: 13
Category: Article
ISSN: 1083-8791
DOI: 10.1016/j.bbmt.2006.12.149

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Idiotype Immunization Following High-Dos

Idiotype Immunization Following High-Dose Therapy and Autologous Stem Cell Transplantation for Non-Hodgkin Lymphoma

✍ Peter R. Holman; Caitlin Costello; Margarida deMagalhaes-Silverman; Sue Corringh 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 195 KB

High dose therapy and autologous stem ce

High dose therapy and autologous stem cell transplantation for human immunodeficiency virus-associated non-Hodgkin lymphoma in the era of highly active antiretroviral therapy

✍ Arturo Molina; Amrita Y. Krishnan; Auayporn Nademanee; Rachel Zabner; Irena Snie 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 114 KB 👁 2 views

Double High Dose Salvage Therapy With Do

Double High Dose Salvage Therapy With Dose-Intensified Cyclophosphamide, Etoposide, and Cisplatin (DICEP) Re-Induction Followed by High-Dose Melphalan (HDM) and Autologous Stem Cell Transplantation (ASCT) Consolidation for Relapsed/Refractory Hodgkin Lymphoma

✍ M. Shafey; Q. Duan; J.A. Russell; P. Duggan; A. Balogh; D.A. Stewart 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 98 KB

Rituximab (anti-CD20 monoclonal antibody

Rituximab (anti-CD20 monoclonal antibody) therapy for progressive intermediate-grade non-Hodgkin’s lymphoma after high-dose therapy and autologous peripheral stem cell transplantation

✍ Tsai, D E; Moore, H C F; Hardy, C L; Porter, D L; Loh, E Y; Vaughn, D J; Luger, 📂 Article 📅 1999 🏛 Nature Publishing Group 🌐 English ⚖ 52 KB

Gemcitabine, Busulfan and Melphalan (Gem

Gemcitabine, Busulfan and Melphalan (Gem/Bu/Mel) Is a New High-Dose Chemotherapy (HDC) Regimen with High Activity in Refractory or Poor-Risk Relapsed Non-Hodgkin'S Lymphoma (NHL) Patients Receiving an Autologous Stem-Cell Transplant (ASCT)

✍ Y. Nieto; R.B. Jones; U. Popat; B. Andersson; B. Valdez; P. Thall; E.J. Shpall; 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 56 KB

Feasibility and Efficacy of High-Dose Me

Feasibility and Efficacy of High-Dose Melphalan, Cyclophosphamide, Etoposide, and Dexamethasone (LEED) Chemotherapy with or without Rituximab Followed by Autologous Stem Cell Transplantation for Aggressive and Relapsed Non-Hodgkin’s Lymphoma

✍ Li-na Han; Jin Zhou; Takayuki Hirose; Yosuke Imai; Takuro Ishiguro; Takaaki Chou 📂 Article 📅 2006 🏛 Carden Jennings Publishing 🌐 English ⚖ 137 KB